pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Arexvy
drug
save

Arexvy

Marketedupdated 3mo ago
by GlaxoSmithKline Biopharmaceuticals inc
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying Arexvy

  • phase2Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Personsrecruitingn=170
  • phase1A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adultsactive not recruitingn=144
  • phase1First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adultscompletedn=160
  • phase1Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adultsrecruitingn=160
  • phase2RSV Vaccination in Immunocompromised Patients.recruitingn=200

News(0)

no news has mentioned this drug yet

brand
Arexvy
indication
Respiratory Syncytial Virus (RSV) Infections
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 34m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?